To the content

Billing Codes

for Rapiblyk® (landiolol) 

The reimbursement information and codes contained in this document are publicly available from third-party sources and are provided for informational purposes only. These codes are not an all-inclusive list and are not intended for, and do not constitute legal, reimbursement, or business advice. The information contained herein represents no statement, promise, or guarantee by AOP Health concerning levels of reimbursement, payment, or charge. Similarly, all codes are supplied for informational purposes only and represent no statement, promise, or guarantee by AOP Health that these codes will be appropriate or that reimbursement will be made. It is the health care provider’s responsibility to accurately report the patient diagnosis, the services provided, and the procedures performed, consistent with the payers’ guidelines.  If providers have questions about coverage, coding, or payment, providers should consult the specific payers. The Center for Medicare and Medicaid Services (CMS) website is available at https://www.cms.gov/.

10 Digit NDC84381-110-01
11 Digit NDC84381-0110-01

DRG-Bundle

Rapiblyk treats supraventricular tachycardia (atrial flutter and atrial fibrillation) which may be associated with the conditions described by the examples below:

DRG CodePatient Cohort
177Respiratory infections and inflammations with mcc
189Pulmonary edema and respiratory failure
193Simple pneumonia and pleurisy with mcc
314Other circulatory system diagnoses with mcc
698Other kidney and urinary tract diagnoses with mcc
853Infectious and parasitic diseases with O.R. Procedures with mcc
854Infectious and parasitic diseases with O.R. Procedures with cc
870Septicemia or severe sepsis with mv >96 hours
871Septicemia or severe sepsis without mv >96 hours with mcc
872Septicemia or severe sepsis without mv >96 hours without mcc
193Simple pneumonia and pleurisy with mcc
246Percutaneous cardiovascular procedures with drug-eluting stent with mcc
or 4+ arteries or stents
280Acute myocardial infarction, discharged alive with mcc
286Circulatory disorders except AMI, with cardiac catheterization with mcc
291Heart failure and shock with mcc
292Heart failure and shock with cc
293Heart failure and shock without cc/mcc
308Cardiac arrhythmia and conduction disorders with mcc
309Cardiac arrhythmia and conduction disorders with cc
310Cardiac arrhythmia and conduction disorders without cc/mcc
216Cardiac valve and other major cardiothoracic procedures with cardiac
catheterization with mcc
219Cardiac valve and other major cardiothoracic procedures without cardiac
catheterization with mcc
220Cardiac valve and other major cardiothoracic procedures without cardiac
catheterization with cc
228Other cardiothoracic procedures with mcc
233Coronary bypass with cardiac catheterization or open
ablation with mcc
234Coronary bypass with cardiac catheterization or open
ablation without mcc
235Coronary bypass without cardiac catheterization with mcc
236Coronary bypass without cardiac catheterization without mcc
266Endovascular cardiac valve replacement and supplement
procedures with mcc
267Endovascular cardiac valve replacement and supplement
procedures without mcc

ICD-10-CM

Arrythmia

Rapiblyk treats supraventricular tachycardia (atrial flutter and atrial fibrillation) which may be associated with the conditions described by the examples below:

Diagnosis CodeDiagnosis Code Label
I47.10Supraventricular Tachycardia, Unspecified
I47.19Other Supraventricular Tachycardia
I48.0Paroxysmal Atrial Fibrillation
I48.1Persistent Atrial Fibrillation
I48.19Other Persistent Atrial Fibrillation
I48.3Typical Atrial Flutter
I48.4Atypical Atrial Flutter
I48.9Unspecified Atrial Fibrillation And Atrial Flutter
I48.91Unspecified Atrial Fibrillation
I48.92Unspecified Atrial Flutter
I47.10Supraventricular Tachycardia, Unspecified
I47.19Other Supraventricular Tachycardia
I48.0Paroxysmal Atrial Fibrillation
I48.1Persistent Atrial Fibrillation
I48.19Other Persistent Atrial Fibrillation
I48.3Typical Atrial Flutter
I48.4Atypical Atrial Flutter
I48.9Unspecified Atrial Fibrillation And Atrial Flutter

Heart Failure

Rapiblyk treats supraventricular tachycardia (atrial flutter and atrial fibrillation) which may be associated with the conditions described by the examples below:

Diagnosis CodeDiagnosis Code Label
I09.81Rheumatic Heart Failure
I11.0Hypertensive Heart Disease With Heart Failure
I13.0Hypertensive Heart And Chronic Kidney Disease With Heart Failure And Stage 1
Through Stage 4 Chronic Kidney Disease, Or Unspecified Chronic Kidney Disease
I13.2Hypertensive Heart And Chronic Kidney Disease With Heart Failure And With Stage 5
Chronic Kidney Disease, Or End Stage Renal Disease
I50.20Unspecified Systolic (Congestive) Heart Failure
I50.21Acute Systolic (Congestive) Heart Failure
I50.22Chronic Systolic (Congestive) Heart Failure
I50.23Acute On Chronic Systolic (Congestive) Heart Failure
I50.30Unspecified Diastolic (Congestive) Heart Failure
I50.31Acute Diastolic (Congestive) Heart Failure
I50.32Chronic Diastolic (Congestive) Heart Failure
I50.33Acute On Chronic Diastolic (Congestive) Heart Failure
I50.40Unspecified Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.41Acute Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.42Chronic Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.43Acute On Chronic Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.810Right Heart Failure, Unspecified
I50.811Acute Right Heart Failure
I50.812Chronic Right Heart Failure
I50.813Acute On Chronic Right Heart Failure
I50.82Biventricular Heart Failure
I50.84End Stage Heart Failure
I50.89Other Heart Failure
I50.9Heart Failure, Unspecified
I97.13Postprocedural Heart Failure

Sepsis

Rapiblyk treats supraventricular tachycardia (atrial flutter and atrial fibrillation) which may be associated with the conditions described by the examples below:

Diagnosis CodeDiagnosis Code Label
A02.1Salmonella Sepsis
A22.7Anthrax Sepsis
A26.7Erysipelothrix Sepsis
A32.7Listerial Sepsis
A40.0Sepsis Due To Streptococcus, Group A
A40.1Sepsis Due To Streptococcus, Group B
A40.3Sepsis Due To Streptococcus Pneumoniae
A40.8Other Streptococcal Sepsis
A40.9Streptococcal Sepsis, Unspecified
A41.0Sepsis Due To Staphylococcus Aureus
A410.1Sepsis Due To Methicillin Susceptible Staphylococcus Aureus
A410.2Sepsis Due To Methicillin Resistant Staphylococcus Aureus
A41.1Sepsis Due To Other Specified Staphylococcus
A41.2Sepsis Due To Unspecified Staphylococcus
A41.3Sepsis Due To Hemophilus Influenzae
A41.4Sepsis Due To Anaerobes
A41.5Sepsis Due To Other Gram-negative Organisms
A41.50Gram-negative Sepsis, Unspecified
A41.51Sepsis Due To Escherichia Coli [E. Coli]
A41.52Sepsis Due To Pseudomonas
A41.53Sepsis Due To Serratia
A41.54Sepsis Due To Acinetobacter Baumannii
A41.59Other Gram-negative Sepsis
A41.8Other Specified Sepsis
A41.81Sepsis Due To Enterococcus
A41.89Other Specified Sepsis
A41.9Sepsis, Unspecified Organism
A42.7Actinomycotic Sepsis
A54.86Gonococcal Sepsis
B37.7Candidal Sepsis
R65.20Severe Sepsis Without Septic Shock
R65.21Severe Sepsis With Septic Shock
T81.12Postprocedural Septic Shock

Hospital Revenue Codes

Rapiblyk treats supraventricular tachycardia (atrial flutter and atrial fibrillation) which may be associated with the conditions described by the examples below:

Revenue CodeDescription
0252Non-generic drugs
0258IV solutions
0260General IV Therapy
0262Pharmacy Services
0631Single Source Drug
To the main navigation

IMPORTANT SAFETY INFORMATION

Contraindications

RAPIBLYK® is contraindicated in patients with:

  • Severe sinus bradycardia
  • Sick sinus syndrome
  • Heart block greater than first degree
  • Decompensated heart failure
  • Cardiogenic shock
  • Pulmonary hypertension
  • Hypersensitivity to landiolol or any of the inactive ingredients

Warning and Precautions

  • Patients with hemodynamic compromise, hypovolemia, or receiving interacting medications are at increased risk of hypotension. Monitor blood pressure closely. Reduce or discontinue RAPIBLYK if hypotension occurs.

  • Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest, may occur. Monitor heart rate and rhythm. Reduce or discontinue RAPIBLYK for bradyarrhythmia.

  • Beta-blockers may cause depression of myocardial contractility and may precipitate heart failure or cardiogenic shock. At the first sign of impending cardiac failure, discontinue RAPIBLYK and initiate supportive therapy.

  • Beta-blockers may exacerbate bronchospasm. Use caution in patients with reactive airway disease. Discontinue infusion if bronchospasm occurs.

  • Beta-blockers may mask symptoms of hypoglycemia (e.g., tachycardia) and may increase the risk for severe or prolonged hypoglycemia. Monitor blood glucose in patients with diabetes or those at risk.

  • Infusion site reactions including pain, swelling, and erythema have occurred. Avoid infusions into small veins or through butterfly catheters. Use an alternative site if reactions develop.

  • Abrupt discontinuation of beta-blocker therapy in patients with coronary artery disease may result in exacerbations of angina, myocardial infarction, or ventricular arrhythmias. Monitor for signs of myocardial ischemia when discontinuing RAPIBLYK.

  • Beta-blockers may increase serum potassium. Monitor electrolytes during therapy, especially in patients with renal impairment.

  • Beta-adrenergic blockade may mask clinical signs of hyperthyroidism. Abrupt withdrawal may precipitate thyroid storm.

  • Patients at risk of anaphylaxis may be more reactive to allergen exposure and may be unresponsive to usual doses of epinephrine.

Adverse Reactions

The most common adverse reaction was hypotension in adults and pediatric patients.

Drug Interactions

  • Avoid concomitant use with negative inotropes or medications that slow heart rate or cardiac conduction.
  • Beta-adrenergic agonists may antagonize the effects of RAPIBLYK.
  • Use caution with catecholamine-depleting drugs due to increased risk of hypotension or bradycardia.
     

For more information about RAPIBLYK, see full Prescribing Information.

­

Indications

RAPIBLYK® (landiolol) for injection is a beta-adrenergic blocker indicated for the short-term reduction of ventricular rate in:

  • Adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter
  • Pediatric patients with supraventricular tachycardia